Clinical Trials

Phase 2 clinical trial entitled A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

ClinicalTrials.gov Identifier

NCT04752813

Principal Investigator

Andrew Brenner, MD, PhD

For more information about this study
View Details

About This Study

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of radiation therapy (RT) and concurrent temozolomide (TMZ) chemotherapy for patients with newly diagnosed glioblastoma (GB).